Compound index

Small-Molecule Drugs

Spironolactone

FDA-approved for specific indicationsFDA-approved

Last reviewed: 2026-11-19

Overview

A steroidal mineralocorticoid-receptor antagonist.

Regulatory status

FDA approval applies only to the named products and indications below. It does not approve every formulation or other use.

  • Aldactone · Cardiovascular Care

    Specified heart failure, hypertension and edema indications; not FDA-approved for hair loss or acne.

    Authoritative label record
  • Aldactone · Endocrine Disorders

    Primary hyperaldosteronism under labeled conditions.

    Authoritative label record

Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.

WADA prohibited status: current list and context

Evidence at a glance

Approved cardiovascular and endocrine uses do not constitute FDA approval for hair-loss or acne indications.

Key sources

Indication-specific regulatory sources and editorial screen checked November 19, 2026. This is not an exhaustive systematic review; consult current labels.

Related compounds

  • Apomorphine

    Same scientific class · A small chemical molecule, not a peptide. · FDA-approved for specific indications

  • Finasteride

    Same scientific class · A small chemical molecule, not a peptide. · FDA-approved for specific indications

  • Metformin

    Same scientific class · A small chemical molecule, not a peptide. · FDA-approved for specific indications

  • Methylthioninium chloride

    Same scientific class · A small chemical molecule, not a peptide. · FDA-approved for specific indications

  • Minoxidil

    Same scientific class · A small chemical molecule, not a peptide. · FDA-approved for specific indications

Related glossary terms